The atmosphere was electric as I settled into my seat at the SDPA Annual Summer Dermatology Conference in San Diego. Marc Serota, MD, a triple board-certified expert in Dermatology, Allergy/Immunology, and Pediatrics, was about to present on chronic urticaria. As a PA, I was eager to absorb every detail. Dr. Serota began by defining chronic …
Join us to learn about “Exploration in Chronic Spontaneous Urticaria,” in this webinar featuring Jane Mast, PhD, DMSc, MPAS, PA-C and Jonathan Rodrigues, MD, Derm/Allergy Medical Directors at Novartis. This webinar is sponsored by Novartis Pharmaceuticals Corporation.
Chronic spontaneous urticaria (CSU), is a condition that is both disabling and common. The first line treatment is with second-generation H1-antihistamines, often at high doses, but this treatment fails to get a complete resolution in symptoms in up to half of patients. A recent study conducted at a referral center for CSU patients examined whether …